SPRO

Spero Therapeutics, Inc.

1.36 USD
+0.08 (+6.25%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Spero Therapeutics, Inc. stock is down -12.82% since 30 days ago. The next earnings date is Aug 8, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 42.86% of the previous 6 June’s closed higher than May.

About Spero Therapeutics, Inc.

Spero Therapeutics, Inc. focuses on identifying, developing, and commercializing treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults.